Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668421 | 0.85 | GRM5 (0.46) | GRM5CHRM1 | |
| SCHEMBL4900008 | 0.84 | GRM5 (0.45) | GRM5CHRM1MEN1MAPK1HTT | |
| SCHEMBL4975875 | 0.80 | L3MBTL1 (0.46) | GRM5MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL4668777 | 0.78 | OPRL1 (0.40) | HTTCHRNA7POLB | |
| SCHEMBL4697311 | 0.77 | OPRL1 (0.46) | — | |
| SCHEMBL4668729 | 0.74 | GRM5 (0.46) | GRM5CHRM1MEN1MAPK1HTT | |
| SCHEMBL4669598 | 0.73 | GRM5 (0.45) | GRM5CHRM1MEN1MAPK1HTT | |
| SCHEMBL4789409 | 0.72 | OPRL1 (0.35) | CHRNA7 | |
| SCHEMBL4981388 | 0.72 | L3MBTL1 (0.47) | GRM5MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL4669629 | 0.70 | KMT2A (0.35) | MEN1KMT2ASRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1896479-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006134485-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | OPRL1, OPRD1, OGFRL1 | GRM5 267/4885CHRM1 49/4885MEN1 3252/4885 |
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | OPRL1, OGFRL1, OPRD1 | GRM5 219/4885CHRM1 195/4885MEN1 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.